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ABSTRACT 
ATP-competitive Fibroblast Growth Factor Receptor (FGFR) kinase inhibitors, including BGJ398 
and Debio1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) 
harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is 
often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we 
report that the irreversible pan-FGFR inhibitor, TAS-120, demonstrated efficacy in four patients 
with FGFR2-fusion-positive ICC who developed resistance to BGJ398 or Debio1347. 
Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells 
revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to 
BGJ398 or Debio1347. Functional assessment and modeling the clonal outgrowth of individual 
resistance mutations from polyclonal cell pools mirrored the resistance profiles observed 
clinically for each inhibitor. Our findings suggest that strategic sequencing of FGFR inhibitors, 
guided by serial biopsies and ctDNA, may prolong the duration of benefit from FGFR inhibition 
in patients with FGFR2 fusion-positive ICC.   
 
STATEMENT OF SIGNIFICANCE 
ATP-competitive FGFR inhibitors (BGJ398, Debio1347) show efficacy in FGFR2-altered ICC; 
however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor 
progression. We demonstrate that the irreversible FGFR inhibitor TAS-120 provides clinical 
benefit in patients with resistance to BGJ398 or Debio1347 and overcomes several FGFR2 
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INTRODUCTION 
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy of the liver bile 
ducts with poor outcomes and rising incidence (1). Most patients are diagnosed with locally 
advanced or metastatic disease, precluding potentially curative resection. Standard of care 
palliative chemotherapy with gemcitabine and cisplatin offers these patients a median survival of 
less than one year (2). ICCs exhibit an array of genomic alterations of known oncogenic drivers 
and tumor suppressors, suggesting the potential of targeted therapies in subsets of patients (3-
6). Recurrent genomic alterations that activate the FGFR pathway are present in ~20% of ICCs 
(3, 6-12). The most common alterations are chromosomal fusions consisting of FGFR2 exons 1 
to 17, encoding the intact extracellular and kinase domains, fused in-frame to a 3′ partner that 
possesses a protein dimerization domain. The resulting chimeric FGFR2 proteins are 
constitutively active and promote proliferation or transformation of several cell types (6, 7, 9). 
The frequency of FGFR2 fusions in ICC is considerably higher than that reported for any other 
malignancy (13)(data retrieved from http://www.cbioportal.org). Activating FGFR2 point 
mutations and amplification or overexpression of FGFR1-3 are also observed in subsets of 
patients with ICC (8, 14).  
Multiple FGFR-selective inhibitors are being tested in clinical trials in patients with ICC 
with FGFR pathway alterations. These second-generation inhibitors represent an improvement 
over the early generation of multi-kinase inhibitors with activity against FGFR (e.g. dovitinib and 
ponatinib), which lack sufficient specificity and potency to effectively treat FGFR-driven tumors. 
The most clinically advanced FGFR-selective compound in cholangiocarcinoma is the ATP-
competitive FGFR1-3 inhibitor, BGJ398 (infigratinib), which demonstrated efficacy in a phase II 
trial of patients with advanced refractory cholangiocarcinoma harboring FGFR fusions, 
amplifications, or point mutations (14). The overall response rate (ORR) in this heavily 
pretreated patient population was 14.8% and the disease control rate (DCR) was 75.4% (18.8% 
and 83.3%, respectively, for patients with FGFR2 fusions only). A Phase 1 dose-escalation trial 
Research. 
on May 30, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 20, 2019; DOI: 10.1158/2159-8290.CD-19-0182 
 5 
using another ATP-competitive FGFR1-3 inhibitor, Debio1347 (CH5183284) (15), has also 
reported early evidence of antitumor activity in a few tumor types including ICC (16). However, 
rapid emergence of acquired resistance was frequently observed, with a 5.8-month median 
progression-free survival in the BGJ398 trial (14). We recently reported genomic 
characterization of pre- and post-progression cell-free circulating tumor DNA (ctDNA) and tumor 
biopsies in three patients with FGFR2 fusion-positive ICCs treated with BGJ398; this study 
revealed the emergence of the FGFR2 V565F gatekeeper mutation at progression in all three 
patients, two of whom also had additional FGFR2 kinase domain mutations (17). Rapid autopsy 
in one patient revealed three different FGFR2 kinase domain mutations in spatially distinct 
metastases, highlighting the additional challenge of inter-lesional heterogeneity in addressing 
acquired resistance to an ATP-competitive FGFR inhibitor in ICC. 
The third-generation, irreversible FGFR inhibitor TAS-120 covalently binds to a highly 
conserved P-loop cysteine residue in the ATP pocket of FGFR (C492 in the FGFR2-IIIb isoform) 
(18). TAS-120 exhibits in vitro potency at low nanomolar concentrations and high specificity 
against wild-type FGFR1-4 as well as against some FGFR2 kinase domain mutations (19). 
Preliminary results from a phase I basket study of TAS-120 in patients with refractory advanced 
solid tumors showed an ORR of 25.0% and a DCR of 78.6% in 28 patients with ICC harboring 
FGFR2 fusions (20), including some patients who had received prior therapy with an ATP-
competitive FGFR inhibitor.   
Here, we report the results of clinical and translational studies of TAS-120 in the 
treatment of patients with FGFR2 fusion-positive ICC who progressed on BGJ398 or 
Debio1347, including patients in whom secondary FGFR2 kinase mutations were detected just 
prior to TAS-120 initiation. We performed complementary studies investigating FGFR2-
mediated signaling mechanisms in ICC models and determined the efficacy of these second- 
and third-generation FGFR inhibitors against clinically observed FGFR2 kinase domain 
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mutations. Our findings reveal genotype-phenotype correlations for drug sensitivity that inform 




TAS-120 provides clinical benefit in patients with ICC with acquired resistance to BGJ398 
or Debio1347 
Among six patients with advanced FGFR2 fusion-positive ICC who received care at our 
institution after progression on BGJ398 or Debio1347 in clinical trials, four subsequently 
enrolled in the phase I trial of TAS-120 (NCT02052778) between November 2015 and 
November 2017. Each of the four patients showed benefit on TAS-120: two of these patients 
achieved a partial response and two achieved stable disease by RECIST v1.1 criteria (Figure 
1A) with a duration of benefit of 5.1 to 17.2 months. We highlight these patients to show proof of 
concept of an irreversible FGFR inhibitor overcoming acquired resistance to an ATP-competitive 
FGFR inhibitor in the clinic and to elucidate the potential molecular determinants of response for 
this observation. The patients’ clinical characteristics and FGFR2 gene alterations are 
summarized in Table 1A and 1B. No additional cancer-relevant genomic alterations were 
detected in the pre-treatment biopsies, with the exception of copy number increases of the 
FGFR1 and MYC loci in the biopsy from patient #3 (see Methods for specific genotyping assays 
used for the different samples).  
 
Patient 1 is a 74-year-old female with recurrent FGFR2-SORBS1 fusion-positive ICC 
metastatic to her liver and lymph nodes. On third-line BGJ398 treatment, she achieved a 
maximum response of -68% followed by progression of all three liver lesions at approximately 
12 months. ctDNA analysis at that time revealed two new FGFR2 kinase domain mutations, 
K660M and K715R (Figure 1B) (amino acids are numbered according to FGFR2-IIIb splice 
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isoform [NM_001144913.1] since FGFR2 fusions in ICC are expressed in this context (21); the 
equivalent mutations in the one amino acid shorter IIIc isoform are K659M and K714R). Biopsy 
of a single liver lesion at the time of progression showed no FGFR2 kinase domain mutations, 
suggesting that these mutations were subclonal or that other molecular mechanisms drove 
resistance in this lesion. The patient subsequently received TAS-120, which resulted in a 
maximum response of -77% and suppression of K660M and K715R below the level of detection 
in ctDNA. After nearly 16 months on TAS-120, she had progression in all liver lesions. A third 
FGFR2 mutation, the gatekeeper V565F, emerged in the ctDNA during the final months of TAS-
120 treatment and was detected in a post-progression tumor biopsy.  
Patient 2 is a 59-year-old female with a FGFR2-ZMYM4 fusion-positive ICC who 
presented with a dominant 15 cm liver mass and metastases to her liver and lungs. She 
achieved a maximum response of -50% on second-line BGJ398 treatment. Scans at 6 months 
showed a mixed response with regression of the dominant mass and progression of satellite 
liver lesions.  ctDNA analysis at that time revealed five mutations in the FGFR2 kinase domain 
(N550H, N550K, V565F, E566A, and K660M). Two of these mutations were observed in a 
tumor biopsy of a progressing satellite liver lesion obtained in parallel — V565F and K660M, as 
previously reported (17)(amino acid numbering is updated here to reflect expression of the 
FGFR2-IIIb splice isoform [NM_001144913.1]) . Upon next line TAS-120 treatment, she 
achieved stable disease with a best response of +8%. Progression occurred at approximately 7 
months, with a mixed response consisting of rebound growth of a previously responsive lung 
lesion, stability of the dominant mass, and continued progression of the biopsied left lobe liver 
lesion. While the spatial location of each mutation was unknown, this heterogeneous response 
to TAS-120 was reflected in ctDNA analysis where levels of some mutations (N550H, K660M) 
dropped below the level of detection before eventually rebounding at the time of disease 
progression, and others stabilized (N550K, E566A) or increased (V565F) during therapy (Figure 
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1C). A sixth FGFR2 mutation (V563L) emerged in ctDNA during TAS-120 therapy and was 
detected in a biopsy obtained upon disease progression.   
Patient 3 is a 28-year-old male with Crohn’s disease and FGFR2-INA fusion-positive ICC 
who presented with a 5.4 cm liver mass concurrently with liver, lung, peritoneal, and lymph node 
metastases. He received second-line Debio1347 treatment to a maximum response of -50% 
followed by disease progression at all sites at nearly 12 months. He then had two post-
progression liver biopsies obtained 2.5 months apart on distinct liver lesions with intervening 
cytotoxic chemotherapy — the first revealed an FGFR2 H683L mutation (CCF=0.23) and the 
second revealed three FGFR2 mutations (N550H, CCF=0.093; N550T, CCF=0.108; and M538I, 
CCF=0.19). TAS-120 treatment was initiated immediately after this second biopsy, and ctDNA 
analysis of plasma collected at this baseline timepoint revealed one of these five mutations 
(H683L) and one additional mutation (L618V). The patient achieved a maximum response of -
22% on TAS-120 treatment and exhibited disease progression at 5.1 months with a mixed 
response in the liver and growth of lung and bone lesions. ctDNA analysis during treatment 
showed a modest decline of L618V and H683L levels (Figure 1D). As the tumor progressed, 
ctDNA analysis revealed the gradual emergence of mutations seen on baseline biopsy (N550H, 
N550T, M538I) and other previously undetectable mutations (V565L, E566A). 
Patient 4 is a 46-year-old male with chronic hepatitis B and recurrent metastatic FGFR2-
NRAP fusion-positive ICC involving his liver. Second-line BGJ398 led to a maximum response 
of -40% but at approximately 7 months, scans showed a mixed response with continued tumor 
shrinkage in the liver and emergence of osseous metastases. No ctDNA sample or tumor 
biopsy was available immediately post-progression to assess for mechanisms of resistance. He 
received palliative spinal radiation, pembrolizumab, T8 metastasectomy, and FOLFOX, with 
progression after each of these treatments. The patient then initiated TAS-120 with a 7-month 
interval between FGFR inhibitors. Analysis of ctDNA just prior to receiving TAS-120 did not 
reveal any detectable molecular alterations, potentially reflecting low levels of shedding of tumor 
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DNA. On TAS-120, this patient achieved a maximum response of -48%, although this benefit 
could not be correlated with the ability of the drug to overcome specific resistance mechanisms.  
The patient eventually experienced growth of a single liver lesion at 17.2 months, and at that 
time, analysis of ctDNA and tumor biopsy demonstrated the emergence of FGFR2 N550K 
(Table 1B).  
These findings extend our prior observations that acquired resistance to FGFR inhibition 
in ICC is associated with the emergence of multiple, heterogeneous tumor subclones harboring 
distinct secondary FGFR2 kinase domain mutations. Importantly, in this setting, TAS-120 
demonstrated marked clinical benefit, highlighting the critical dependence of these tumors on 
sustained FGFR signaling and pointing to the importance of these FGFR2 kinase domain 
mutations as a common mechanism of clinical acquired resistance to FGFR inhibition. 
Collectively, the assessment of clonal dynamics in ctDNA suggests that TAS-120 has 
differential activity against individual FGFR2 secondary mutations compared to ATP-competitive 
FGFR inhibitors. Understanding the spectrum of activity of various FGFR inhibitors against 
commonly observed acquired FGFR2 mutations may lead to strategies to overcome or delay 
resistance.  
 
FGFR signaling is critical for MEK/ERK activity and viability in FGFR+ ICC models 
In order to study FGFR-driven signaling and examine candidate resistance mutations in 
a biologically relevant context, we developed a panel of patient-derived biliary tract cancer cell 
lines and tested these and established biliary tract cancer lines for response to FGFR inhibitors. 
Treatment of these cell lines with BGJ398 revealed that ICC13-7 and CCLP-1 cells were highly 
sensitive (IC50 5-15 nM), whereas the other lines tested were resistant (IC50 200-3000 nM) 
(Figure 2A). Similar profiles were seen in response to the more potent TAS-120 compound, 
with ICC13-7 and CCLP1 cells showing increased sensitivity (IC50, 0.6-1.5 nM) compared to 
the rest of the lines (IC50, 300-8000 nM) (Figure 2B). Accordingly, immunoblot analysis of 
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lysates from 11 ICC cell lines and of immortalized bile duct cells (MMNK-1) showed that only 
ICC13-7 and CCLP1 cells had detectable levels of phosphorylated Fibroblast Growth Factor 
Receptor Substrate 2 (pFRS2 Y196), consistent with constitutive FGFR signaling 
(Supplementary Figure S1A). Genomic analysis revealed that ICC13-7 cells harbored an 
FGFR2-OPTN fusion (Supplemental Figure S1B), whereas all other cell lines lacked FGFR 
fusions. Moreover, while CCLP-1 cells lacked fusions, intragenic mutations, or copy number 
gains of FGFR genes, they showed greatly increased expression of wild type FGFR1 (IIIc 
isoform) as well as the FGF20 ligand compared to the other cell lines analyzed 
(Supplementary Figure S1C-E). Thus, biliary tract cancer cell lines with activating molecular 
alterations in the pathway are specifically dependent on FGFR signaling for growth in vitro.  
FGFR signaling engages a series of downstream effectors in different normal and 
pathologic contexts (22). We examined the principle pathways controlled by FGFR signaling in 
the ICC13-7 and CCLP-1 cell lines by BGJ398 treatment and immunoblot analysis using 
phospho-specific antibodies. BGJ398 treatment (50 nM) led to rapid inhibition of the MEK/ERK 
pathway as reflected by decreased pFRS2 (Y196), pSHP2 (Y542), pMEK1/2 (S217/221), and 
pERK1/2 (T202/Y204), whereas minimal effects were observed on the PI3K pathway, as 
determined by pAKT (T308 and S473) (Figure 2C, D). Dose-response studies showed effective 
targeting of FGFR2 signaling and downstream inhibition of MEK/ERK at BGJ398 concentrations 
consistent with the cell viability IC50 data (Supplemental Figure S1F); comparable data were 
seen for TAS-120 and Debio1347. In many types of cancer, strong feedback mechanisms exist 
to restore MEK/ERK signaling in response to loss of upstream activators of the pathway (23), 
and these may limit benefit of certain therapeutics that involve MEK/ERK inhibition. Notably, the 
inhibition of MEK/ERK signaling was durable in both cell lines, with no evidence of pathway 
reactivation for up to 3 days for BGJ398 treatment (Figure 2C, D).  
To corroborate these results in vivo, we screened a collection of patient-derived 
xenograft (PDX) models of ICC for FGFR alterations, and identified a model harboring a 
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FGFR2-KIAA1217 fusion (designated MG69) (Supplemental Figure S1G). Treatment of MG69 
PDX tumors with TAS-120 (starting when the volume reached ~500 mm3) led to tumor 
regression and complete proliferative arrest, with prominent effects evident within three days 
and persisting over a 14-day course (Figure 2E, F). Moreover, FGFR inhibition suppressed 
MEK/ERK and SHP2 activity, but not PI3K signaling, in MG69 PDX tumors (Figure 2G). Thus, 
FGFR activated ICC models are highly dependent on FGFR activity to sustain growth and 
maintain MEK/ERK signaling in vitro and in vivo.   
 
TAS-120 overcomes multiple clinically observed FGFR kinase domain mutations  
To gain insight into the clinical landscape of secondary FGFR2 resistance mutations, we 
subsequently leveraged our FGFR-driven ICC cell line models to study the spectrum of FGFR2 
kinase domain mutations emerging upon clinical acquired resistance to BGJ398 (N550K, 
V565F, E566A, K660M, and K715R) or Debio1347 (M538I, H683L), or to both (N550H, L618V). 
We engineered these mutations into a retroviral vector expressing the FGFR2-PHGDH fusion, 
which we observed in an ICC (see Methods). CCLP-1 cells were infected with retroviruses 
expressing the FGFR2-PHGDH fusion with a wild type or mutant FGFR2 kinase domain or 
empty vector control. Of the mutations that arose in patients treated with BGJ398, N550K, 
L618V, and K660M resulted in prominent resistance to the drug in vitro (25- to 39-fold increase 
in IC50), with the V565F gatekeeper conferring the greatest level of resistance (326-fold) 
(Figure 3A, top panel; Supplementary Figures S2A and B show immunoblots for expression 
of the FGFR2 fusions and crystal violet staining of cells at a single drug concentration). The 
N550H and E566A mutants caused weaker effects (7- to 8-fold) and K715R did not affect 
BGJ398 sensitivity. The latter variant involves a residue located outside the BGJ398 binding 
pocket and not implicated in the conformational dynamics of the kinase (17), and thus may not 
represent a functionally relevant mutation. Finally, BGJ398 remained effective against the 
M538I and H683L mutations (3- to 4-fold increase in IC50), which were found in the setting of 
Research. 
on May 30, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 20, 2019; DOI: 10.1158/2159-8290.CD-19-0182 
 12 
clinical resistance to Debio1347 treatment and have not been observed clinically upon BGJ398 
therapy.  
Debio1347 had a distinct profile of sensitivity (Figure 3A, middle panel). The magnitude 
of resistance provoked by the different mutants was lower than that observed for BGJ398, 
although this drug is considerably less potent against FGFR signaling overall. The most 
pronounced resistance to Debio1347 was seen with the N550K, L618V, and K660M mutations 
(12- to 17-fold increase in IC50), while M538I, N550H, and E566A produced intermediate 
effects (4- to 8-fold), H683L had a modest effect, and K715R did not significantly affect 
responsiveness to the drug. Moreover, Debio1347 was relatively effective against the V565F 
gatekeeper mutation (only 3-fold IC50 increase). Notably, TAS-120 showed only minimal or 
modest changes in activity against each of the acquired FGFR2 mutations (2- to 7-fold IC50 
increase) with the exception of V565F (103-fold) (Figure 3A, bottom panel). 
To extend these findings, we modeled clonal outgrowth during acquired resistance using 
a pooled clone system, in which all nine mutant clones were pooled at an initial abundance of 
1% amidst a background of cells expressing the WT FGFR2 fusion (Figure 3B and 
Supplementary Figure S2C). Clonal pools were exposed to different concentrations of each 
FGFR inhibitor for 14 days, and the change in relative clonal abundance under the selective 
pressure of therapy was determined by ddPCR (24). Outgrowth of K715R was not observed 
under any treatment condition, again suggesting that this mutation is not a functional resistance 
alteration. Notably, treatment with 50 nM BGJ398 led to outgrowth of the resistance mutations 
observed in patients 1 and 2 (N550H, N550K, V565F, E566A, K660M) or previously observed 
(17) in the setting of BGJ398 resistance (e.g. L618V). By contrast. BGJ398 prevented the 
outgrowth of M538I detected only in Patient 3 who was treated with Debio1347. Conversely, 
outgrowth of each of these mutations was observed upon treatment with 200 nM Debio1347, 
with the exception of V565F, consistent with the clinical course of Patient 3. Finally, in the 
presence of 10 nM TAS-120 only outgrowth of V565F, and to a lesser extent, E566A, and 
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N550K, were observed. Of note, these were the same three mutations that did not decrease in 
abundance in Patient 2 during TAS-120 therapy (Figure 1C). Interestingly, higher 
concentrations of BGJ398 or TAS-120 were able to suppress outgrowth of all resistance 
mutations with the exception of V565F, highlighting the potential importance of drug exposure in 
suppressing resistant clones. 
We next used the pooled clone system to model the effects of sequential FGFR inhibitor 
therapy, treating clonal pools sequentially with BGJ398 and then TAS-120 to mirror the clinical 
course of Patients 1, 2, and 4 (Figure 3C). Three of the mutations (K660M, N550H, and L618V) 
that emerged during BGJ398 treatment decreased in abundance when treatment was switched 
to TAS-120, consistent with our ctDNA analyses showing that TAS-120 led to decreases in the 
clonal abundance in K660M (Patient 1 and 2), N550H (in Patient 2), and L618V (in Patient 3). 
Conversely, V565F continued to increase and E566A and N550K levels stabilized, but failed to 
decrease upon TAS-120 treatment, similar to the clinical observations in ctDNA from Patient 2.  
Thus, our model systems accurately mirrored the clonal dynamics of individual resistance 
mutations observed in ctDNA analysis from patients treated with TAS-120 after progression on 
BGJ398 or Debio1347.  
Signaling studies corroborated the cell viability findings. CCLP-1 cells expressing 
N550K, V565F, L618V, and K660M retained robust levels of pFRS2, pSHP2, pMEK, and pERK 
upon treatment with 50 nM BGJ398, whereas signaling by the other mutants was inhibited 
partially (N550H, E566A) or strongly (H683L) (Figure 3D and Supplemental Figure S2A). 
Treatment with TAS-120 (50 nM) effectively suppressed signaling by all mutants except V565F. 
Finally, Debio1347 (200 nM) showed reduced potency against most of the mutants but 
remained relatively active against the V565F gatekeeper mutation compared to the other two 
inhibitors. All three inhibitors were effective against K715R. We confirmed our findings for a 
subset of the FGFR2 mutants in ICC13-7 cells via cell viability assays and immunoblot for 
signaling proteins (Supplemental Figure S2D-F). Thus, we demonstrate in relevant in vitro ICC 
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models that TAS-120 has activity against multiple secondary FGFR2 resistance mutations, 
which likely accounts for the benefit of TAS-120 seen in patients who previously progressed on 
BGJ398 or Debio1347. 
We conducted in silico structural modeling to gain insight into the molecular basis for the 
drug response profiles. TAS-120 docks into the ATP binding pocket of FGFR2, with its 
acrylamide group forming a covalent bond with the sulfhydryl group of FGFR2-C492 (Figure 4A 
and B). As with BGJ398 (17, 25), the dimethoxy phenyl group of TAS-120 is in close contact 
with the V565 gatekeeper residue. Accordingly, modeling data indicate that TAS-120 and 
BGJ398 resistance to V565F is due to steric clash preventing access of these drugs into the 
ATP-binding pocket. TAS-120 remains effective against V565I (19), likely due to less severe 
hindrance caused by the smaller isoleucine side chain. Debio1347 lacks the bulky dimethoxy 
phenyl group, and rather possesses a benzimidazole moiety predicted to have stabilizing 
contacts with V565F, which may account for its relative potency against FGFR2 V565F (15). 
Notably, TAS-120 retained activity against several mutations that confer BGJ398 and 
Debio1347 resistance by altering conformational dynamics of FGFR2 rather than directly 
interacting with mutated residues. In particular, N550H/K and E566A stabilize the active 
conformation of the kinase by disrupting a network of hydrogen bonds that serve as an 
autoinhibitory molecular break, K660M forces the A loop of the kinase into an active 
conformation, and L618V disrupts stabilizing interactions between this residue and an Asp–
Phe–Gly (DFG) motif that otherwise favors binding of BGJ398 and Debio1347 (17, 26). Thus, 
BGJ398 and Debio1347 appear not to act on the active kinase conformation, whereas the 
covalent binding mode of TAS-120 may permit effective target engagement irrespective of 
conformation, as observed for the irreversible pan-FGFR inhibitor, FIIN-2 (27). Finally, the 
specific impairment of Debio1347 activity versus FGFR2 M538I may relate to interactions with 
the adjacent M539 residue that contribute to the binding of this drug. Overall, the distinct 
structural features and binding modes of these FGFR inhibitors are in keeping with their specific 
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activity profiles suggested by the clinical data and observed in preclinical models. A recent 
report defining the binding mode of TAS-120 with FGFR1 based on mass spectrometry and X-
ray crystallography analyses is in line with our in silico structural modeling study (18).  
 
DISCUSSION 
In this study, we report that the irreversible FGFR inhibitor, TAS-120, can overcome 
acquired resistance to the ATP-competitive inhibitors, BGJ398 and Debio1347, and provide 
clinical benefit in patients with advanced refractory FGFR2 fusion-positive ICC previously 
treated with these agents. We also find that the spectrum of secondary FGFR2 resistance 
mutations differs across agents and that structural studies of these agents bound to FGFR 
provide a molecular basis for these differences. Finally, we demonstrate that preclinical ICC 
models with activation of the pathway are specifically dependent on FGFR signaling for growth 
and sustained SHP2/MEK/ERK signaling, and that TAS-120 retains efficacy against FGFR2 
kinase domain mutations in this setting. Collectively, these data highlight the FGFR-driven 
oncogene addiction of a defined subset of ICC and support the clinical utility of TAS-120 in 
patients with acquired resistance to second generation FGFR inhibitors.  
The efficacy seen across several early phase clinical trials of FGFR2 inhibitors in 
patients with advanced refractory ICC (14, 28-30) represents a breakthrough in a disease with 
no FDA-approved targeted therapies to date. However, as seen with other tyrosine kinase 
inhibitors, the rapid emergence of resistance associated with recurrent acquired mutations in the 
target’s kinase domain has limited the durability of benefit to ATP-competitive inhibitors. TAS-
120 was designed to overcome FGFR kinase domain mutations, taking advantage of the 
improved potency and specificity afforded by its covalent binding mode and distinct orientation 
in the ATP-binding pocket of FGFRs. This irreversible binding also permanently disables 
FGFR2 enzymatic activity, thus providing the potential advantage of extended 
pharmacodynamic duration without the need for maintaining high drug levels. Covalent small 
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molecule kinase inhibitors have demonstrated success in multiple malignancies and have 
gained FDA approval in EGFR mutant non-small cell lung cancer (afatinib, osimertinib), 
ERBB2/HER2 mutant breast cancer (neratinib), and BTK mutant chronic lymphocytic leukemia, 
Waldenstrom’s macroglobulinemia, and mantle cell lymphoma (ibrutinib)(31). 
We evaluated the efficacy of TAS-120, BGJ398, and Debio1347 against the spectrum of 
nine clinically observed secondary FGFR2 kinase domain mutations using ICC cell lines and 
serial ctDNA analysis. The inhibitors exhibit unique in vitro profiles, and the key findings 
included: a) the mutations that conferred greatest resistance to BGJ398 were N550K, V565F, 
L618V, and K660M; b) the mutations that conferred greatest resistance to Debio1347 were 
N550K, L618V, and K660M, c) Debio1347 largely retained activity against the V565F 
gatekeeper mutation; and d) TAS-120 remained active against all mutations except V565F, with 
modest reduction in activity against E566A and N550K. Additional studies will be required to 
determine the impact of these kinase domain mutations on FGFR2 fusion protein stability and 
turnover and also on the kinetics of signaling re-activation upon inhibitor withdrawal. Moreover, 
it will be important to establish the extent to which pre-existing FGFR2 mutations impact time to 
treatment failure, as observed in EGFR mutant non-small-cell lung cancer (32).  
The clonal dynamics observed with serial ctDNA analysis may hold important 
implications for the clinical management of patients with these resistance alterations. ddPCR 
analysis of ctDNA showed that the mutation allele frequencies for several FGFR2 mutations 
decreased upon TAS-120 treatment — K660M in patient 1, N550H and K660M in patient 2, and 
L618V and H683L in patient 3 — pointing to the activity of TAS-120 against these alleles in the 
clinic. Similarly, the sustained increase or emergence of V565F upon TAS-120 in patients 1-3 is 
consistent with the in vitro resistance studies, as was the lack of reduction in levels of E566A 
and N550K. These data, if validated prospectively in larger clinical cohorts, may provide support 
for a new paradigm in which particular FGFR resistance mutations, detected in serial ctDNA or 
tumor biopsies, could inform the choice of subsequent FGFR targeted therapies. The precedent 
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for this is emerging in advanced ALK fusion positive NSCLC where specific ALK kinase domain 
mutations that arise at the time of crizotinib resistance determine which second-generation 
inhibitor should be used for next line treatment (33). To guide such strategies in ICC, it will be 
important to also establish the full spectrum of mechanisms of resistance to TAS-120, including 
validating the functional impact of V563L, which emerged upon progression on TAS-120 
treatment in patient 2. Notably, whereas resistance to other irreversible kinase inhibitors 
frequently arises due to mutations of cysteine residues that mediate covalent binding (34, 35), 
no mutations at the covalent binding site of TAS-120 (C492) were identified in any of the four 
patients studied in the present report.  
A key challenge in the administration of pan-FGFR inhibitors remains 
hyperphosphatemia-related dose holds and dose reductions. One patient in this study had such 
a dose hold on TAS-120 (see Methods) and two had such dose holds on BGJ398. 
Hyperphosphatemia is a class effect of FGFR inhibitors arising from on-target pathway blockade 
of FGF23-FGFR1 signaling in the renal tubule (22, 36). Notably, we found that clonal outgrowth 
of multiple mutations occurred more readily at lower concentrations of BGJ398 (Fig. 3B), 
highlighting that reduced drug exposure may play an important role in the emergence of 
resistance. While further studies are needed to establish the impact of toxicity-related drug 
modifications on treatment response, the clinical experience highlights the importance of 
aggressive hyperphosphatemia management and the urgency to develop FGFR2-selective 
agents.  
While ctDNA analysis serves as a useful, non-invasive tool for diagnosing resistance 
and monitoring response to therapy, our studies also illustrate the importance of a 
comprehensive approach to studying drug resistance. In patient 3, the three FGFR2 mutations 
identified in the baseline TAS-120 liver biopsy sample went undetected by both targeted 
sequencing and ddPCR in the corresponding plasma sample, possibly reflecting low tumor 
shedding and emphasizing the complementary benefits of tumor biopsy and ctDNA analysis. In 
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patient 1, two FGFR2 kinase domain mutations arose at the time of progression on BGJ398 but 
only one conferred resistance in functional modeling, underscoring the importance of 
functionally validating putative resistance mutations discovered on ctDNA or tumor tissue 
analysis.  
 In keeping with the clinical data, our preclinical studies demonstrate that ICC models 
with constitutive activation of FGFR signaling are strongly dependent on the pathway. FGFR 
inhibitor treatment of FGFR-driven ICC cell lines and a PDX model led to growth inhibition as 
well as potent and durable inactivation of the SHP2/MEK/ERK pathway. Unlike breast and 
gastric cancers with high level FGFR2 amplification (37), FGFR signaling in these ICC models 
was not additionally coupled to the PI3K/AKT pathway. These findings highlight the distinct 
signaling outputs of oncogenic FGFR signaling in different cancer contexts and point to 
SHP2/MEK/ERK as a likely major effector of the pathway in ICC. The data are consistent with 
SHP2/MEK/ERK activation being the principle effector of FGFR in normal physiology (38) and 
with the frequent presence of concurrent PIK3CA activating mutations with FGFR2 fusions in 
ICC indicating the potential independence of these pathways (14). While our studies suggested 
that FGFR2 fusions with different partners had comparable outputs, further studies will be 
required to fully address the potential differential impact of N-terminus partners on oncoprotein 
localization, inhibitor sensitivity, and downstream signaling targets, as reported for fusions 
involving the ROS1 RTK (39).  
In summary, we demonstrate that strategically sequencing FGFR inhibitors can prolong 
the duration of benefit from FGFR inhibition in patients with FGFR2 fusion-positive ICC.  
Moreover, resistance profiles differ across agents and may evolve under the selective pressure 
of sequential FGFR inhibitors. However, FGFR2-independent resistance may emerge as an 
additional issue that can limit the potential of these next-generation inhibitors. As the clinical 
development of FGFR inhibitors pushes forward, it will be critical to incorporate tumor biopsies 
at baseline and progression and serial ctDNA analysis into clinical trials. These complementary 
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analyses can facilitate our understanding of resistance and elucidate the biology underlying 
heterogeneous responses. Overall, this approach of tailoring FGFR-targeted strategies based 
upon resistance mechanisms detected in serial ctDNA and tumor biopsies may provide a new 
standard of care for this disease.    
 
ACKNOWLEDGEMENTS 
This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, 
through the Peer Reviewed Cancer Research Program, under Award No. W81XWH-17-1-0491 
(N.B., A.X.Z.) and Award No. W81XWH-16-1-0267 (L.Y.L.). Opinions, interpretations, 
conclusions and recommendations are those of the authors and are not necessarily endorsed 
by the Department of Defense. Additional support was provided by the following: MGH Fund for 
Medical Discovery Award (L.G., L.S.), Cholangiocarcinoma Foundation Andrea Lynn Scott 
Memorial Research Fellowship, American Cancer Society Institutional Research Grant, and NIH 
Loan Repayment Program (L.G.). Cholangiocarcinoma Foundation Christopher J. Wilke 
Memorial Research Fellowship (L.S). American Cancer Society Postdoctoral Fellowship PF-16-
120-01-TBG (L.Y.L.). Hope Funds for Cancer Research Fellowship and Harvard Catalyst 
KL2/CMeRIT Fellowship (S.R.). TargetCancer Foundation, Evan Schumacher Fund for Rare 
Cancer Research (S.R, R.N). NIH/NCI 1K08CA194268-01 (S.K.S). The Starr Foundation I11-
0040 (R.Y.). Memorial Sloan-Kettering Cancer Center Core Grant P30 CA 008748 (J.J.H, R.Y.). 
NCI U01 CA176058, U01 CA199253, U01 CA224146 (W.C.H.). HMS Laboratory for Systems 
Pharmacology Grant (P50GM107618) and the Susan Eid Tumor Heterogeneity Initiative (D.J.). 
U54CA224068 (R.B.C.). V Foundation for Cancer Research Translational Grant (N.B, C.H.B., 
L.G.). NCI SPORE P50 CA127003 (N.B., C.H.B, R.B.C). Gallagher Chair in Gastrointestinal 




on May 30, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 20, 2019; DOI: 10.1158/2159-8290.CD-19-0182 
 20 
Patients 
Patients provided written informed consent to treatment on the phase II trial of BGJ398 
(NCT02160041), phase I trial of Debio1347 (NCT01948297), and phase 1 trial of TAS-120 
(NCT02052778). On the phase II trial of BGJ398, the patients received 125mg orally daily on 
days 1 to 21 of each 28-day cycle. On the phase I trial of Debio1347, the patient received 110 
mg orally daily continuously on days 1 to 28 of each 28-day cycle.  On the phase I dose 
escalation or expansion phase of the trial of TAS-120, the patients received 16 to 24 mg orally 
daily of TAS-120 continuously on days 1 to 21 of each 21-day cycle, and all dose reductions 
and safety assessments were performed per protocol for all 3 trials. The TAS-120 dosing for 
each patient was as follows: Patient #1 (16mg); Patient #2 (24mg); Patient #3 (20mg); and 
Patient #4 (16mg). The timing, reason, and duration of the first dose hold for each patient is as 
follows:  Patient #1 (Cycle 14, Day 1; grade 3 motor neuropathy; 15 days); Patient #2 (Cycle 1, 
Day 8; hyperphosphatemia; 7 days); Patient #3 (Cycle 3, Day 1; Grade 2 ALT and AST 
elevation; 7 days); and Patient #4 (Cycle 14, Day 19; palliative XRT; 12 days).  The timing, 
reason, and dosing for the first and subsequent dose reductions for each patient is as follows: 
Patient #1 (Cycle 15, Day 1, reduced to 12mg PO QD for grade 4 creatine kinase elevation and 
remained at this dose until progression); Patient #2 (Cycle 3, Day 1, reduced to 16mg PO QD 
due to hyperphosphatemia and again on Cycle 3, day 15 to 8mg PO QD due to 
hyperphosphatemia; remained at this dose until progression); Patient #3 (Cycle 3, Day 15, 
reduced to 16mg PO QD due to grade 2 AST and ALT elevation, remained at this dose until 
progression); and Patient #4 (no dose reductions). 
 
Computed tomography and/or magnetic resonance imaging scans were performed at baseline 
and every 6 to 9 weeks to assess for tumor response by RECIST version 1.1 criteria. The 
clinical and genomic data relating Patient #2’s treatment prior to TAS-120 therapy have been 
reported previously (17). All biopsies, tumor specimens, and peripheral blood draws for plasma 
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isolation were collected and analyzed in accordance with Institutional Review Board–approved 
protocols, to which patients provided written informed consent, and all studies were conducted 
in accordance with the Declaration of Helsinki.  
 
Reporting of FGFR2 mutations 
We report FGFR2 kinase domain mutations as the amino acid number of the FGFR2-IIIb splice 
isoform [NM_001144913.1], which is the primary isoform expressed in FGFR2 fusion-positive 
ICC (21), Commercial genotyping tests (e.g. Guardant) and our prior report (17) designate 
mutations using the one amino acid shorter FGFR2-IIIc isoform (NM_000141.4) as the 
reference sequence.   
 
Targeted Sequencing of Tumor Tissue 
DNA derived from the primary tumor and metastases were analyzed using deep-coverage 
targeted sequencing of key cancer-associated genes. Targeted sequencing was performed in 
the setting of clinical care via the SNaPshot platform, the FoundationOne platform, or MSK-
IMPACT and the methodology has been previously described (40, 41). Clinical genotyping 
platforms utilized on biopsies after progression on the ATP-competitive inhibitor were as follows:  
Patients #1 and #2 (FoundationOne), Patients #3 (MSK-IMPACT), and Patient #4 (no biopsy 
performed). After progression on TAS-120, the assays used on biopsies were as follows:  
Patient #1 (MGH SNaPshot), Patient #2 (FoundationOne), Patient #3 (no biopsy performed), 
and Patient #4 (MGH SNaPshot).  In Patients #1, #2, and #4, no other cancer-relevant genomic 
alterations besides the FGFR2 fusion were detected in the treatment-naïve tissue sample taken 
at initial diagnosis or at diagnosis of advanced disease; MGH SNaPshot was used for Patient #1 
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Solid Fusion Assay 
Our internal tumor-profiling assay was performed on RNA extracted from formalin-fixed paraffin-
embedded (FFPE) specimens as part of routine clinical care. The SFA is a targeted RNA-
sequencing method of Anchored Multiplex PCR to detect FGFR2 fusions, and the methodology 
has been previously described  (42) . Mutational profiling was performed at the Clinical 
Laboratory Improvement Amendments (CLIA)–certified Translational Research Laboratory at 
the Massachusetts General Hospital Cancer Center. 
 
Droplet Digital PCR  
DNA template (8 to 10 μL) was added to 10 μL of ddPCR Supermix for Probes (Bio-Rad) and 2 
μL of the custom primer/probe mixture. This reaction mix was added to a DG8 cartridge together 
with 60 μL of Droplet Generation Oil for Probes (Bio-Rad) and used for droplet generation. 
Droplets were then transferred to a 96-well plate (Eppendorf) and then thermal cycled with the 
following conditions: 5 minutes at 95°C, 40 cycles of 94°C for 30 seconds, 55°C for 1 minute 
followed by 98°C for 10 minutes (Ramp Rate 2°C/sec). Droplets were analyzed with the QX200 
Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was 
performed based on positive and negative controls, and mutant populations were identified. The 
ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain Fractional 
Abundance of the mutant DNA alleles in the wild-type/normal background. The quantification of 
the target molecule was presented as the number of total copies (mutant plus wild-type) per 
sample in each reaction. Fractional Abundance is calculated as follows: F.A. % = 
(Nmut/(Nmut+Nwt))*100), where Nmut is the number of mutant events and Nwt is the number of 
wildtype events per reaction. ddPCR analysis of normal control plasma DNA (from cell lines) 
and no DNA template controls were always included. Probe and primer sequences are available 
upon request.  
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Targeted Sequencing of Circulating Cell-Free Tumor DNA (ctDNA) 
Cell-free DNA was extracted from whole blood, and 5 ng–30 ng of ctDNA was isolated. 
Sequencing libraries were prepared with custom in-line barcode molecular tagging, and 
complete sequencing at 15,000× read depth of the critical exons in a targeted panel of 70 genes 
was performed at a CLIA-certified, College of American Pathologists–accredited laboratory 
(Guardant Health)(43).  
 
 
Whole exome sequencing (WES) 
WES was performed by the Broad Institute sequencing platform. WES of matched pretreatment 
and post-progression biopsies and normal blood was performed as previously described (44).  
 
Cell culture  
Established cell lines were obtained from the following sources: Riken Bioresource Center 
(HuCCT1, RBE, SSP-25, HuH-28), Korean Cell Line Bank (SNU1079). We are grateful from the 
kind gifts of CCLP-1 and CCSW-1 cells from Dr. P.J. Bosma (Academic Medical Center, 
Amsterdam, the Netherlands), SG231 from Dr. A.J. Demetris (University of Pittsburgh, 
Pittsburgh, PA), and MMNK-1 from Dr. J. Luyendyk (University of Kansas Medical Center, 
Kansas City, KS). Cell lines were grown at 37°C under 5% CO2 in their required growth medium 
(Gibco) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. To 
generate patient-derived biliary tract cancer cell lines (ICC13-7, ICC14, ICC15, ICC16, ICC17, 
ICC18, GB2), we utilized resection or autopsy specimens directly or following growth as patient-
derived xenografts, as per our Institutional Review Board approved protocol (DFCI, #13-162). 
Samples were minced with sterile razor blades, digested with trypsin for 30 minutes at 37°C, 
and then resuspended in RPMI supplemented with 20% fetal bovine serum, 1% L-glutamine 
(Gibco, #25030-081), 1% MEM Non-Essential Amino Acids Solution (Gibco, #11140-050), 1% 
Research. 
on May 30, 2019. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 20, 2019; DOI: 10.1158/2159-8290.CD-19-0182 
 24 
Sodium Pyruvate (Gibco, #11360-070), 0.5% penicillin/streptomycin, 10 μg/mL gentamicin 
(Gibco, #15710-064), and 0.2 Units/mL human recombinant insulin (Gibco, #12585-014) and 
seeded on plates coated with rat tail collagen (BD Biosciences). Cells were passaged by 
trypsinization, adapted to RPMI supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin and transferred to uncoated tissue-culture plates prior to functional 
studies. They were routinely checked to be mycoplasma free. HuCCT1, RBE, SSP-25, HuH-28 
and SNU1079 cells were authenticated by short tandem repeat (STR) DNA profiling by the cell 
line bank from which they were obtained. Authentication by STR DNA profiling through the 
ATCC was performed for CCLP-1, CCSW-1, SG231, MMNK-1, ICC2, and ICC4 (between 
December 2015 and March 2016) and ICC13-7, ICC14, ICC15, ICC16, ICC17, ICC18, and GB2 
(January and April 2018). All cell lines were used within 20 passages of establishment from 
patients or receipt from repositories.  
 
Generation of wild type and mutated FGFR2-PHGDH expressing cell lines 
A FGFR2-PHGDH fusion construct, containing exons 1-17 of FGFR2-IIIb fused to PHGDH 
(NM_006623.3) exons 6-12, was amplified from reverse transcribed cDNAs from an ICC patient 
sample and inserted into the pMSCV vector using the NEBuilder HiFi DNA Assembly (New 
England Biolabs). All FGFR2 mutations were introduced into the pMSCV vector using the same 
kit. Targeted Sanger sequencing was done to confirm mutation generated. Retrovirus was 
generated by transfecting the pMSCV constructs and packaging plasmids into 293T cells. After 
collection of retrovirus, transfected 293T cells were collected to confirm protein expression from 
each construct. Viral infections of CCLP-1 and ICC13-7 cells were performed in the presence of 
polybrene. Infected cells were selected in blasticidin (6-15 ug/ml) for one to two weeks. For both 
cell lines, he period of time in culture between thawing, infection, selection, recovery, and 
experimental setup and completion was less than 10 passages. 
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Cell viability assay 
For IC50 measurement using the FGFR inhibitors, cells were dissociated into single cells and 
seeded into a 384-well tissue culture plate, each well with 200 viable cells and 40µL of growth 
medium. After 24 hours, compounds were added to each well over a 15-point concentration 
range, along with DMSO controls, using a Tecan D300e digital drug dispenser. Cells were 
cultured for 5 days in the presence of compound before assessing viability by adding 15µL of 
Cell Titer-Glo (Promega) to each well, incubating for 20 minutes at room temperature on a 
shaker, and measuring luminescence using an Envision plate reader. Each condition was 
performed in 5 replicates, and each dose point was normalized to DMSO controls to estimate 
relative viability. At least 2 independent experiments were performed for each compound and 
cell line. IC50 values were determined by GraphPad Prism using a 4-parameter dose-response 
model. Crystal violet staining assays were done by seeding cells into 6-well plates one day 
before addition of drug. Cells were grown in the presence of drug for four days (CCLP-1 cells) or 
two weeks (ICC13-7 cells), then washed with PBS, fixed with cold methanol, stained with 0.5% 
crystal violet solution (Sigma-Aldrich), and washed extensively under tap water.   
 
Immunoblot analysis 
Cells were treated with drugs in 6-well plates for 5-8 hours or as indicated. Cell protein lysates 
were prepared in ice-cold RIPA lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 2mM EDTA, 
1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, containing Roche protease inhibitors and 
Calbiochem phosphatase inhibitor cocktail set I and II). Debris was removed by centrifugation in 
a microfuge at max speed for 10 min at 4 C. Protein concentration in clarified lysate was 
determined by Pierce BCA protein assay (Thermo Fisher Scientific). Ten micrograms of protein 
were used to perform analysis by SDS-PAGE, electro-transfer and immunoblotting with specific 
antibodies. The following antibodies were used: from Cell Signaling Technology (all at 1:1000 
dilution): phospho-FRS2 Y196 (3864S), SHP2 (3397S), phospho-MEK1/2 S217/221 (9154S), 
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MEK1/2 (4694S), phospho-ERK1/2 T202/Y204 (9106S), ERK1/2 (4695S), phospho-AKT T308 
(13038S), phospho-AKT S473 (4060S), AKT (9272S), FGFR1 (9740S); from Abcam (1:5000 




Total RNA from cell lines was extracted using the RNeasy Mini Kit (Qiagen). RNA (1 μg) was 
reverse transcribed using SuperScript™ II Reverse Transcriptase (Invitrogen) or reagents from 
the QuantiTect Rev. Transcription Kit (Qiagen), according to the manufacturer’s instructions. 
Quantitative RT-PCR (qRT-PCR) was performed on a CFX384 Real-Time PCR Detection 
System (Bio-Rad) with iTaq Universal SYBR Green Supermix, 2X (Bio-Rad). FGFR1-3 and 
FGF20 were analyzed by qRT-PCR. Data was normalized for expression of the housekeeping 
gene ribosomal 18S. Primer sequences are provided in Supplementary Table S1. 
 
PDX treatment studies 
Mice were housed in pathogen-free animal facilities. All experiments were conducted under 
protocol 2005N000148 approved by the Subcommittee on Research Animal Care at 
Massachusetts General Hospital. To develop an FGFR2 fusion human PDX, we obtained tissue 
from a fresh resection specimen from a patient with an FGFR2-KIAA1217 fusion ICC tumor, per 
our IRB-approved protocol (DFCI# 13-162). The tissue was rinsed in HBSS and cut into 0.3-0.5 
mm3 pieces with sterile razor blades. These tumor pieces were implanted subcutaneously into 
6-8-week old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, 00557, The Jackson 
Laboratory). Tumor size was measured with a digital caliper. Upon reaching ~500 mm3, mice 
were randomized to either vehicle control or 25 mg/kg TAS-120 (in hydroxypropyl methyl 
cellulose solution) by oral gavage daily for three and fourteen days prior to harvest. Tumor 
samples were collected for biochemical analysis and histology processing. For histology 
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processing, tissue samples were fixed overnight in 4% buffered formaldehyde, embedded in 
paraffin, and then sectioned and stained with haematoxylin and eosin by the MGH Pathology 
Core. Immunohistochemistry (IHC) was performed on paraffin-embedded sections (5 μ m 
thickness). After deparaffinization and dehydration, slides were incubated for 10 min with 3 % 
H2O2 at room temperature to block endogenous peroxidase activity. Specimens were brought to 
the boil in 10 mM sodium citrate buffer (pH 6.0, 5 min, pressure cooker) for antigen retrieval. 
Slides were blocked for 1 hour in TBS-0.05 % Tween 20 (Fisher Scientific), 1 drop per 1 ml of 
Protein Block (Dako X0909) and incubated with primary antibody for 1 hour at room 
temperature. Primary anti-Ki-67 antibody (Abcam, ab15580) was diluted in with PBS-Protein 
Block (1 drop/ml) at a ratio of 1:400 and incubated with the tissue sections at 4˚C. Specimens 
were reacted for 30 min with the ImmPRESS HRP polymer reagent (Vector Labs) combined 
with secondary antibodies. Slides were then washed with PBS and stained for peroxidase for 1–
2 min with the Betazoid DAB Chromogen reagent, washed with water and counterstained with 
haematoxylin. Stained slides were photographed with an Olympus DP72 microscope. 
 
Population growth modeling with clonal pool system 
Cell pools containing 1% of each mutant cell line and 90% of FGFR2-PHGDH WT cells were 
seeded at low confluency in 6-well plates. We used 1% as an empirically chosen concentration 
which allowed growth of cells in the presence of different FGFR inhibitors for 2-weeks without 
individual mutant clones overtaking the entire population. This percentage was also sufficiently 
high to enable clone detection by ddPCR. Every experimental condition was performed in 
triplicate. Two independent experiments were used to generate data for Figures 3B and C. Drug 
incubation (or DMSO-treated controls) started 24h after cell seeding and drug treatment was 
refreshed every 3-4 days. After 1, 7 or 14 days in culture, the remaining cells were trypsinized 
and collected for genomic DNA extraction. Genomic DNA extracted from cells using the DNeasy 
Blood and Tissue Kit (Qiagen) was subjected to enzymatic fragmentation with either MseI or 
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HaeIII, and amplified using ddPCR Supermix for Probes (Bio-Rad) using FGFR2 assays 
(PrimePCR ddPCR Mutation Assay, Bio-Rad, and custom-designed). DNA template (20-40ng) 
was added to 12.5 μL of ddPCR Supermix for Probes (Bio-Rad) and 1.25 μL of the primer/probe 
mixture. This reaction mix (final volume = 25μL) was added to a DG8 cartridge together with 70 
μL of Droplet Generation Oil for Probes (Bio-Rad) and used for droplet generation. Droplets 
were then transferred to a 96-well plate (Eppendorf) and then thermal cycled with the following 
conditions: 10 minutes at 95°C, 40 cycles of 94°C for 30 seconds, 55°C for 1 minute followed by 
98°C for 10 minutes (ramp rate 2°C/second). Droplets were analyzed with the QX200 Droplet 
Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was performed 
based on positive and negative controls, and mutant populations were identified. The ddPCR 
data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance 
of the mutant DNA alleles in the wild-type (WT)/normal background. The quantification of the 
target molecule was presented as number of total copies (mutant plus WT) per sample in each 
reaction. Fractional abundance is calculated as follows: F.A. % = (Nmut/(Nmut + Nwt)) × 100), 
where Nmut is number of mutant events and Nwt is number of WT events per reaction. The 
number of positive and negative droplets is used to calculate the concentration of the target and 
reference DNA sequences and their Poisson-based 95% confidence intervals, as previously 
described (45). Multiple replicates (minimum of three) were performed for each sample. ddPCR 
analysis of normal control genomic DNA from cell lines and no DNA template (water) controls 
was performed in parallel with all samples, including multiple replicates as contamination-free 
controls. 
 
In Silico Structural Modeling 
TAS-120 was docked into FGFR2 (PDBID: 1OEC). The loop structure (V488-V496) was 
modeled so that the S atom of C492 and the terminal carbon of acrylamide in TAS-120 made a 
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1A.  Clinical characteristics and outcomes of patients with FGFR2 fusion-positive 
cholangiocarcinoma receiving FGFR inhibitors. 




Figure 1. TAS-120 is clinically effective in FGFR2 fusion-positive ICC patients whose 
tumors acquired resistance to BGJ398 or Debio1347. 
A, Radiologic scans of patients 1-4 during the course of FGFR inhibitor therapy. 
B-D, ddPCR analysis of serial ctDNA samples from patients 1-3. Time periods of therapy with 
the specific FGFR inhibitors are indicated by shading. MAF: mutant allele frequency. Mutations 
identified in tumor biopsies taken at the indicated times are presented at the bottom of each 
graph.  CCF: cancer cell fraction.  
 
Figure 2. FGFR-activated ICC models show FGFR2-dependent growth and MEK/ERK 
signaling in vivo and in vitro 
A. Graph of IC50 data and dose response curves for BGJ398 in biliary tract cancer cell lines 
that show constitutive FGFR activation (red) or lack FGFR activity (black). p < 0.0002 for IC50 
difference. 
B. Graph of IC50 data and dose response curves for TAS-120 in biliary tract cancer cell lines. p 
< 0.002 for FGFR-activated versus non-FGFR-activated lines. * denotes IC50 was not reached.  
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C and D, Immunoblot of signaling effects of 50 nM BGJ398 treatment versus vehicle control in 
ICC13-7 cells (C) and CCLP-1 cells (D). Cells were treated for the indicated times before 
harvesting. 
E-G. Fragments of an ICC PDX harboring an FGFR2-KIAA1217 fusion were implanted in NSG 
mice. Mice were randomized for treatment with TAS-120 (25 mg/kg) or vehicle once tumors 
reached ~500 mm3. E, Histologic images (H&E staining) and measurement of proliferation (Ki67 
staining) of tumors isolated at the indicated times. F, Serial measurement of tumor volumes. G, 
Immunoblot data showing signaling inhibition upon TAS-120 treatment (samples are from 14 
days treatment). 
 
Figure 3. FGFR inhibitors have distinct activity profiles against secondary FGFR2 kinase 
mutations in ICC cell lines that correlate with clinical data. 
A-D, CCLP-1 cells were engineered by retroviral transduction to express the FGFR2-PHGDH 
fusion with a wild type kinase domain or harboring the indicated mutations, or empty vector. The 
fusions contain the FGFR2-IIIb splice isoform [NM_001144913.1], and the amino acids are 
numbered accordingly. A, Graphs of IC50 measurements upon treatment with the indicated 
FGFR inhibitors.  The measured IC50 is also indicated numerically at the right along with the 
fold-change in IC50 of each cell line relative to cell lines expressing the WT fusion. Red shading 
highlight mutants conferring a greater than 10-fold increase in IC50. B, Pooled CCLP-1 cell 
clones of all FGFR2 fusion variants were treated with BGJ398, Debio1347, or TAS-120 at the 
indicated concentrations over 14 days. The individual clones were monitored using genomic 
DNA extracted at 14 days, using a ddPCR assay specific to each mutation. Data are mean ± 
SEM of triplicate determinants of relative change in clonal abundance compared with the start of 
treatment and are generated from two independent experiments. C, Clonal pools as in (B) were 
treated sequentially with 50 nM BGJ398 and 10nM TAS-120 to mimic the treatment course of 
patients. Cells were monitored at 7 and 14 days. Data are expressed in relative mutant allele 
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frequency compared with the start of treatment. Data are mean ± SD of triplicate determinants 
of relative change in clonal abundance compared with the start of treatment and are generated 
from two independent experiments. D, Immunoblot of CCLP-1 cells expressing the different 
FGFR2-PHGDH alleles following treatment with the indicated inhibitor concentrations. 
 
Figure 4. Structural modeling of secondary FGFR2 kinase domain mutations with TAS-
120. 
A, Model showing TAS-120 docked into ATP-binding pocket of wild type FGFR2. Amino acid 
residues corresponding to mutations conferring resistance to ATP competitive FGFR inhibitors 
are highlighted. Structural representations were prepared using PyMOL. 
B, A close-up view of TAS-120 in ATP-binding pocket of wild type FGFR2. The gatekeeper 
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Between 1st and 2nd 
FGFR inhibitor 
Interval Between 1st and 







1 FGFR2-SORBS1 BGJ398 12.6 -68.2% None 1.2 TAS-120 15.8 -76.7% 
2 FGFR2-ZMYM4  BGJ398 5.6 -49.9% None 1.6 TAS-120 7.2 +8.3% 
3 FGFR2-INA  Debio1347 11.4 -49.5% 
Gemcitabine/Docetaxel, 
T11 palliative radiation 
3.0 TAS-120 5.1 -22.1% 
4 FGFR2-NRAP  BGJ398 7.1 -40.0% 
T8 palliative radiation, 
Pembrolizumab, 
Resection of T8 
metastasis, FOLFOX 
7.4 TAS-120 17.2 -47.7% 
PFS = Progression Free Survival, BOR = Best Overall Survival 
 
Table 1b: FGFR2 mutations detected in cfDNA and tumor biopsies 
Patient 
ID 
FGFR2 Fusion  
Post-Progression BGJ398/Debio1347, Prior to TAS-120 Post-Progression TAS-120 
cfDNA Tumor Biopsy cfDNA Tumor Biopsy 
1 FGFR2-SORBS1 K660M, K715R None Detected V565F& V565F&& 
2 FGFR2-ZMYM4  
V565F, K660M, E566A, 
N550H, N550K 
V565F&&, K660M&& 
V565F, K660M, E566A, N550H, 
N550K, V563L 
V563L 
3 FGFR2-INA  H683L&, L618V& 
Biopsy #1: H683L 
Biopsy #2: N550H, N550T, M538I  
V565L, E566A, N550H, L618V, 
N550T&, M538I& 
No Biopsy Obtained 
4 FGFR2-NRAP  None Detected No Biopsy Obtained N550K N550K 
All mutations were detected on CLIA-certified assays as a routine part of clinical care except those designated with an 
&(detected on ddPCR only) or &&(detected on WES only). 
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Response to TAS-120
Baseline Nadir Progression
-40.0% response -47.7% response
-49.5% response -22.1%
Response to Prior ATP-Compe��ve FGFR Inhibitor
Baseline Nadir Progression
-68.2% response -76.7% response
-49.9% response +8.3%
Biopsy:
No FGFR2 mutations detected
Biopsy:
FGFR2 V565F (CCF 0.88)
BGJ398 TAS-120





































































FGFR2 V565F (CCF 0.1)
FGFR2 K660M (CCF 0.43)
Biopsy:
FGFR2 V563L (CCF 0.69)






























FGFR2 N550H (CCF 0.09)
  FGFR2 N550T (CCF 0.11)
  FGFR2 M538I (CCF 0.19)
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